erlotinib hydrochloride has been researched along with metformin in 12 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (metformin) | Trials (metformin) | Recent Studies (post-2010) (metformin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 17,793 | 3,176 | 12,526 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Galani, V; Georgiou, I; Kitsou, C; Kosmas, IP; Lazaros, L; Markoula, S; Mynbaev, O; Peschos, D; Prapas, I; Prapas, N; Tournaye, H; Zikopoulos, A | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Klein, JD; Sands, JM | 1 |
| Duell, T; Gaertner, S; Genzel, R; Knyazev, PG; Morresi-Hauf, A; Ullrich, A; Xiao, Z | 1 |
| Accordino, MK; Crew, KD; Fenn, K; Hershman, DL; Kalinsky, K; Lee, SM; Maurer, M; Trivedi, MS | 1 |
| Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC | 1 |
| Li, G; Lin, Z; Mei, J; Xu, X | 1 |
1 review(s) available for erlotinib hydrochloride and metformin
| Article | Year |
|---|---|
Physiological insights into novel therapies for nephrogenic diabetes insipidus.
Topics: Adenylate Kinase; Animals; Aquaporin 2; Diabetes Insipidus, Nephrogenic; Erlotinib Hydrochloride; Humans; Metformin; Mutation; Phosphorylation; Receptors, Vasopressin; Sildenafil Citrate; Simvastatin | 2016 |
3 trial(s) available for erlotinib hydrochloride and metformin
| Article | Year |
|---|---|
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MAP Kinase Signaling System; Maximum Tolerated Dose; Metformin; Middle Aged; Progression-Free Survival; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2020 |
8 other study(ies) available for erlotinib hydrochloride and metformin
| Article | Year |
|---|---|
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Metformin and erlotinib synergize to inhibit basal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Metformin; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Topics: AMP-Activated Protein Kinases; Animals; Capillary Permeability; Chorionic Gonadotropin; Erlotinib Hydrochloride; Everolimus; Female; Follicle Stimulating Hormone; Hormones; Infliximab; Metformin; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Reproductive Control Agents; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diabetes Mellitus, Type 2; ErbB Receptors; Erlotinib Hydrochloride; Humans; Metformin; Mice; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2017 |
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure | 2020 |
Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors | 2021 |